Repligen Stock And 2 Dollar Beneficiaries Gaining Attention After Fed Rate Shift

Rising tensions between the United States and Iran, firmer expectations of a September Federal Reserve rate hike, and a stronger U.S. dollar have quickly reshaped the opportunity set for dollar earners. With oil prices up 4% and markets watching U.S. inflation data and Fed commentary closely, some large, financially solid companies that report in U.S. dollars could be positioned differently to others. This article looks at 3 stocks from our U.S. Dollar Beneficiaries screener that appear positively exposed to these currency and rate moves. It is intended to help you decide whether they deserve a closer look or a spot on your watchlist.

Repligen (RGEN)

Overview: Repligen is a life sciences company that supplies equipment, consumables and analytics used to make complex biological drugs, from hollow fiber filters and chromatography systems to process monitoring tools, selling mainly to biopharmaceutical companies, contract manufacturers and research labs.

Operations: Repligen generates about US$763.3 million of revenue from medical products, with around US$366.5 million from North America, US$263.7 million from Europe and US$133.2 million from Asia Pacific and the rest of the world.

Market Cap: US$8.1b

Repligen gives you exposure to a specialist supplier at the heart of biologic drug production, with revenue tied to global life sciences spending and a business that benefits when a stronger U.S. dollar lifts the value of overseas sales. Analysts expect earnings and revenue to grow faster than the wider U.S. market, and recent Q1 2026 results showed higher revenue and net income alongside raised full year EPS guidance. At the same time, the stock has been under pressure as investors worry about biotech funding, product mix volatility and index removals, while Repligen continues to invest heavily in manufacturing and APAC expansion. That combination of growth potential, currency tailwinds and real execution risks means the full Repligen story is more nuanced than the headline numbers suggest.

Repligen’s growth story looks powerful, but the real question is how much risk is hiding behind the headline guidance and currency benefits. That is exactly what the 4 key rewards and 1 important warning sign starts to uncover.

Sandisk (SNDK)

Overview: Sandisk develops, manufactures and sells NAND flash based storage solutions, providing solid state drives, embedded storage and removable flash products used in data centers, PCs, smartphones, IoT devices and other connected hardware worldwide.

Operations: Sandisk generates about US$13.2b of revenue from developing, manufacturing, marketing and selling data storage devices and solutions.

Market Cap: US$283.7b

Sandisk sits at the center of AI and cloud infrastructure, supplying NAND memory for data centers and edge devices as AI workloads and storage needs expand. A stronger U.S. dollar can lift the translated value of its substantial international sales. Analysts have cited factors such as technology like BiCS8 and BiCS10, multiyear supply agreements and high forecast returns on equity, while also noting that the stock trades on a rich P/E with limited upside to price targets and that recent insider selling and board turnover raise governance questions. Understanding how the interaction between growth, pricing power, valuation and governance could affect Sandisk may require examining detailed financial data and contract structures rather than focusing only on headlines.

Sandisk’s accelerating role in AI and cloud storage is only half the story, especially with rich P/E and fresh governance questions in the mix, so it is worth reading the 2 key rewards and 2 important warning signs to see what might be hiding in plain sight

Neuren Pharmaceuticals (ASX:NEU)

Overview: Neuren Pharmaceuticals is a biopharmaceutical company focused on neurological disorders, with its lead drug DAYBUE targeting Rett syndrome and a second candidate, NNZ-2591, being developed for several rare genetic conditions such as Phelan-McDermid, Angelman and Pitt Hopkins syndromes.

Operations: Neuren Pharmaceuticals currently generates about A$64.6 million from commercial products and a small A$0.02 million from corporate activities, with all reported revenue coming from the United States.

Market Cap: A$2.1b

Neuren Pharmaceuticals stands out in this U.S. Dollar Beneficiaries screener because its growing U.S. royalty stream and functional link to the U.S. dollar sit alongside forecasts for strong earnings and revenue growth. At the same time, the stock is flagged as trading well below estimated fair value. The recent research showing Phelan-McDermid syndrome may be more common than previously thought, combined with DAYBUE’s existing U.S. market and a pipeline of NNZ-2591 indications, highlights a business with meaningful optionality. However, there are also real risks tied to a single commercial partner, regulatory decisions and external funding. Investors considering Neuren Pharmaceuticals may wish to weigh a high P/E, funding structure considerations and currency exposure against its growth profile and rare disease focus in the context of a stronger U.S. dollar environment.

Neuren Pharmaceuticals sits at the crossroads of rare disease optionality and U.S. dollar royalty power, yet few investors fully connect the dots between its growth profile and the analyst forecasts for Neuren Pharmaceuticals hiding one critical twist.

The three U.S. dollar beneficiaries in this article are only a sample of the opportunity. The full U.S. Dollar Beneficiaries screener surfaces 44 more large cap companies built around equally compelling currency, cash flow and balance sheet stories. Use Simply Wall St to identify and analyze the specific catalysts and narratives that matter to you so you can focus on the highest conviction ideas across this U.S. dollar theme.

Take Control of Your Investment Journey

If Neuren Pharmaceuticals or any of these companies sound like a great opportunity, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value the ideal entry point. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Beyond These Picks?

Fresh ideas get caught early, before the crowd piles in and momentum starts flying. Screen for potential breakouts while it matters and aim to secure your own edge by acting early.

• Spot potential early movers with strong cash generation and balance sheets by scanning the curated 45 high quality undervalued stocks before they move out from under the radar.
• Explore structural demand for electricity and grid upgrades by reviewing the hand picked 34 power grid technology and infrastructure stocks while these infrastructure stories are still being repriced.
• Consider long term robotics opportunities by sorting through the focused 32 robotics and automation stocks before leading automation names see their entry points change.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com